Key Takeaways
- MaaT Pharma partners with Clinigen for exclusive distribution of MaaT013 in Europe.
- The agreement includes an upfront payment and potential for milestone payments tied to regulatory approval.
- Early Access Program requests for MaaT013 surged by 75% from 2023 to 2024, now managed by Clinigen.
Partnership Announcement
MaaT Pharma, a French biotech company, has entered into a licensing and distribution agreement with UK-based Clinigen. This strategic move aims to facilitate the potential commercialization of its lead microbiome therapy, MaaT013, specifically targeting acute graft-versus-host disease (aGvHD) in Europe.
Under the terms of the deal, Clinigen secures exclusive rights to distribute MaaT013, contingent upon the therapy receiving regulatory approval from the European Medicines Agency (EMA). The agreement includes an upfront payment of 10.5 million euros (approximately $11.3 million), in addition to potential milestone payments that could total up to 18 million euros. Furthermore, Clinigen will receive royalties in the mid-thirties percentage range based on net sales of the therapy.
Both companies anticipate that this collaboration will enhance market access across Europe, particularly amidst a growing clinical demand for MaaT013. Notably, requests through the Early Access Program for this therapy saw a significant increase of 75% between 2023 and 2024. This program, which has been operating since 2019, will now be managed by Clinigen. The intention behind this transition is to streamline patient access and alleviate some of the operational burdens faced by MaaT Pharma.
This partnership exemplifies the commitment of both organizations to meet the pressing needs of patients suffering from aGvHD, as they aim to capitalize on heightened interest and demand for innovative treatment options in the European market. The potential benefits of this agreement highlight the growth trajectory of MaaT Pharma and the increasing role of collaborative efforts in advancing healthcare solutions.
Clinigen’s expertise in market access and distribution is expected to play a crucial role in the success of MaaT013, should it secure EMA approval. The collaboration reflects a strategic alignment of capabilities in navigating the complexities of the European pharmaceutical landscape.
Overall, this agreement marks a significant step for MaaT Pharma as it seeks to expand its reach and impact in the biotechnology field while addressing critical health challenges facing patients in Europe. The collaboration is positioned to not only enhance the accessibility of MaaT013 but also to potentially lead to broader advancements in treatment for aGvHD and similar conditions.
The content above is a summary. For more details, see the source article.
